



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Abdominal aorta, MR angiography of, 124–131, 133
for aneurysms, 127–129
for aortic dissection, 129
for aortic occlusion, 129–130
for renal artery stenosis, 130
for renal transplant evaluation, 130–131, 133
- Adenomas, adrenal, MR imaging of, 153–154
hepatocellular, MR imaging of, 59–60
serous microcystic, MR cholangiopancreatography of, 107
- Adenomyosis, MR imaging of, 183
- Adrenal glands, MR imaging of, 145–146, 152–157
for adenomas, 153–154
for adrenocortical carcinoma, 154–155
for cysts, 156–157
for myelolipomas, 156
for pheochromocytomas, 155–156
for pseudocysts, 156–157
technique for, 145–146
- Adrenocortical carcinoma, MR imaging of, 154–155
- Alcoholic pancreatitis, MR cholangiopancreatography of, 102–103
- Aneurysms, abdominal aortic, MR angiography of, 127–129
thoracic aortic, MR angiography of, 35–36
- Angiomyolipomas, MR imaging of, 148–150
- Aortic aneurysms, abdominal, MR angiography of, 127–129
thoracic, MR angiography of, 35–36
- Aortic dissection, abdominal, MR angiography of, 129
thoracic, MR angiography of, 34–35
- Aortic occlusion, abdominal, MR angiography of, 129–130
- Arrhythmogenic right ventricular dysplasia, MR imaging of, 21–22

- Arterial obstruction, hepatic, MR imaging of, 85
- Atherosclerotic plaque, MR imaging of, 21

B

- Bicornuate uterus, MR imaging of, 181–182
- Biliary complications, postoperative, MR cholangiopancreatography of, 92–93
- Biliary cystadenomas, MR imaging of, 60
- Biliary cysts, MR cholangiopancreatography of, 90–91
- Bladder, MR imaging of, **161–177**
anatomy in, 162
for cystoceles, 173–175
for diverticula, 171–172
for endometriosis, 172–173
for lymphomas, 170
for mesenchymal tumors, 170–171
for tumors, 162–170
contrast-enhanced, 167–168
direct spread, 165–167
epidemiology of, 162–163
management and follow-up, 169–170
metastatic to bones, 168–169
metastatic to lymph nodes, 169
primary mass, 163–165
for vesical congestion and inflammation, 172
patient preparation for, 161
planes in, 161–162
pulse sequences in, 161–162
- Blood pool agents, in MR angiography, 140
- Bolus-chase MR angiography, technique for, 134–136, 138
- Breast cancer, screening for, MR imaging in, 49–50
- Breasts, MR imaging of, **43–50**
contrast-enhanced, 44–45
for fibroadenomas, 47–48
image analysis in, 45–49

- patient preparation for, 44
 - techniques for, 44
 - to screen for breast cancer, 49–50
- Budd-Chiari syndrome, MR imaging of, 84–85
- Bypass graft patency, MR imaging of, 20–21

- C**

- Cardiac masses, MR imaging of, 24
- Cardiomyopathies, MR imaging of.
 - See* Cardiovascular disease.
- Cardiovascular system, MR imaging of, **17–28**
 - for cardiac masses, 24
 - for cardiomyopathies, 21–23
 - arrhythmogenic right ventricular dysplasia, 21–22
 - dilated, 23
 - hemochromatosis, 23
 - hypertrophic, 22
 - restrictive, 23
 - for congenital heart disease, 25
 - for coronary arteries, 19–21
 - anomalous arteries, 20
 - atherosclerotic plaque, 21
 - bypass graft patency, 20–21
 - Kawasaki disease, 20
 - MR angiography in, 19–20
 - for ischemic heart disease, 17–19
 - contrast-enhanced, 18–19
 - myocardial viability in, 17
 - rest imaging, 17
 - stress imaging, 17–18
 - for pericardial disease, 23–24
 - for valvular heart disease, 21
- Central thoracic veins, MR angiography of, 37
- Cervical cancer, MR imaging of, 186–187
- Chest, MR angiography of, **29–41**
 - contrast-enhanced, 29–31
 - for aortic aneurysms, 35–36
 - for aortic dissection, 34–35
 - for central thoracic veins, 37
 - for developmental anomalies, 36
 - for pulmonary arteries, 37–39
 - for thoracic aorta, 34
 - image analysis in, 34
 - pulse sequences in, 32–33
 - techniques for, 29–34
- Cholangiocarcinoma, MR cholangiopancreatography of, 93–94
 - MR imaging of, 62–63
- Cholecystolithiasis, MR cholangiopancreatography of, 91
- Choledocholithiasis, MR cholangiopancreatography of, 91–92
- Cirrhosis, MR imaging of, 68–74
- Congenital heart disease, MR imaging of, 25
- Congestive heart failure, hepatic effects of, 85
- Contrast enhancement, of MR angiography,
 - of abdominal aorta, 116, 118–131, 133
 - of chest, 29–31
 - of MR imaging, of bladder tumors, 167–168
 - of breasts, 44–45
 - of cardiovascular disease, 18–19
 - of hepatic tumors. *See* Hepatic tumors.
- Coronary arteries, MR angiography of, 19–21
- Cystadenocarcinoma, MR imaging of, 188
- Cystadenomas, biliary, MR imaging of, 60
- Cystoceles, bladder, MR imaging of, 173–175
- Cysts, adrenal, MR imaging of, 156–157
 - biliary, MR cholangiopancreatography of, 90–91
 - hepatic, MR imaging of, 56–57
 - renal, MR imaging of, 151–152

- D**

- Dermoids, MR imaging of, 185
- Diffuse hepatic disease, MR imaging of, **67–87**
 - arterial obstruction, 85
 - Budd-Chiari syndrome, 84–85
 - cirrhosis, 68–74
 - congestive heart failure, 85
 - fatty liver, 77–79
 - hemochromatosis, 23, 79–80
 - hepatitis, 74–75, 77
 - hepatocellular carcinoma, 62, 81
 - lymphomas, 81
 - metastatic disease, 81
 - mucopolysaccharidoses, 80–81
 - portal vein thrombosis, 81, 84
 - technique for, 67–68
 - vascular disorders, 81
- Dilated cardiomyopathy, MR imaging of, 23
- Diverticula, bladder, MR imaging of, 171–172
- Dobutamine stress imaging, of cardiovascular disease, 17–18
- Double-duct sign, in MR cholangiopancreatography, 105

Duct-penetrating sign, in MR cholangiopancreatography, 105

E

Echo planar MR imaging, physics of, 9–12

Endometrial cancer, MR imaging of, 187–188

Endometriosis, MR imaging of, 172–173, 183

Endoscopic retrograde cholangiopancreatography, *versus* MR cholangiopancreatography, 89, 99–100

F

Fast spin echo MR imaging, physics of, 6–7, 9

Fatty liver, MR imaging of, 77–79

Female pelvis, MR imaging of, **179–192**

anatomy in, 179–181

for adenomyosis, 183

for cervical cancer, 186–187

for dermoids, 185

for endometrial cancer, 187–188

for endometriosis, 183

for fetal anomalies, 190–191

for fibroids, 182–183

for müllerian anomalies, 181–182

for ovarian cancer, 188

for pelvic floor relaxation, 188–189

for polycystic ovarian disease, 184–185

for tubo-ovarian complex, 185–186

in pregnancy, 189–190

technique for, 179

Ferumoxides, in MR imaging, 53–54

Fetal anomalies, MR imaging of, 190–191

Fibroadenomas, of breasts, MR imaging of, 47–48

Fibroids, uterine, MR imaging of, 182–183

Focal nodular hyperplasia, hepatic, MR imaging of, 58–59

H

Half-Fourier acquisition single-shot turbo spin echo sequence, in MR imaging, 52, 68

Hamartomas, renal, MR imaging of, 148–150

Hemangiomas, hepatic, MR imaging of, 57–58

Hemochromatosis, MR imaging of, 23, 79–80

Hepatic disease, diffuse. *See* Diffuse hepatic disease.

Hepatic tumors, MR imaging of, **51–65**

biliary cystadenomas, 60

cholangiocarcinoma, 62–63

contrast-enhanced, 52–53

ferumoxides in, 53–54

gadolinium chelates in, 52–53

hepatocyte-selective, 54–55

perfusional, 55–56

cysts, 56–57

focal nodular hyperplasia, 58–59

hemangiomas, 57–58

hepatocellular adenomas, 59–60

hepatocellular carcinoma, 62, 81

metastatic disease, 60–62, 81

T1-weighted sequences in, 51–52

T2-weighted sequences in, 52

Hepatitis, MR imaging of, 74–75, 77

Hepatocellular adenomas, MR imaging of, 59–60

Hepatocellular carcinoma, MR imaging of, 62, 81

Hepatocyte-selective contrast agents, in MR imaging, 54–56

Hypertrophic cardiomyopathy, MR imaging of, 22

I

Intraductal papillary mucinous tumors, MR cholangiopancreatography of, 107–110

Iron deposition, hepatic, MR imaging of, 79–80

Ischemic heart disease, MR imaging of.
See Cardiovascular system.

K

Kawasaki disease, MR imaging of, 20

Kidneys, MR imaging of, 145–152

for angiomyolipomas, 148–150

for cysts, 151–152

for lymphomas, 150

for metastatic disease, 150–151

for preoperative planning, 152

for renal cell carcinoma, 146–148

technique for, 145–146

Klatskin's tumors, MR cholangiopancreatography of, 93–94

L

Leiomyomas, bladder, MR imaging of, 170
uterine, MR imaging of, 182–183

Leriche's syndrome, MR angiography of, 129–130
 Liver tumors. *See* Hepatic tumors.
 Lung cancer, metastatic to kidneys, MR imaging of, 150–151
 Lymph nodes, involvement of, by bladder tumors, MR imaging of, 169
 Lymphomas, bladder effects of, MR imaging of, 170
 hepatic effects of, MR imaging of, 81
 renal effects of, MR imaging of, 150

M

Magnetic resonance imaging, of adrenal glands.
 See Adrenal glands.
 of bladder. *See* Bladder.
 of breasts. *See* Breasts.
 of cardiovascular system.
 See Cardiovascular system.
 of diffuse hepatic disease. *See* Diffuse hepatic disease.
 of female pelvis. *See* Female pelvis.
 of hepatic tumors. *See* Hepatic tumors.
 of kidneys. *See* Kidneys.
 physics of, **1–15**
 conventional image acquisition, 3
 image data, 2–3
 motion artifacts, 3
 motion compensation approaches to, 3–5
 pulse sequences, 5–7, 9–12, 161–162
 echo planar imaging, 9–12
 fast spin echo imaging, 6–7, 9
 spiral imaging, 9–12
 reduction of data collection in, 12–14
 requirements and challenges of, 1
 Mangafodipir, in MR imaging, 54–55
 Mesenchymal tumors, bladder, MR imaging of, 170–171
 Metastatic disease, to bones, MR imaging of, 168–169
 to kidneys, MR imaging of, 150–151
 to liver, MR imaging of, 60–62, 81
 MR angiography, contrast-enhanced, 116, 118–124
 bolus delivery in, 123–124
 pulse sequences in, 121–123
 timing of, 119–121
 future directions in, 138–140
 of abdominal aorta. *See* Abdominal aorta.
 of chest. *See* Chest.
 of coronary arteries, 19–21

of peripheral arterial occlusive disease, 133–136, 138
 bolus chasing in, 134–136, 138
 phase-contrast, 115–116
 time-of-flight, 115–116

MR cholangiopancreatography, of pancreatic diseases. *See* Pancreatic diseases.

MR urography, technique for, 146

Mucinous cystic neoplasms, MR cholangiopancreatography of, 107

Mucopolysaccharidoses, MR imaging of, 80–81

Müllerian anomalies, MR imaging of, 181–182

Myelolipomas, MR imaging of, 156

Myocardial viability, MR imaging of, 17

N

Neurofibromas, bladder, MR imaging of, 170

O

Ovarian cancer, MR imaging of, 188

P

Pancreas divisum, MR cholangiopancreatography of, 91, 101

Pancreatic diseases, MR cholangiopancreatography of, **89–96, 97–114**

 anatomy in, 100–101

 biliary congenital variants, 91

 biliary cystic diseases, 90–91

 cancer, 94

 cholangiocarcinoma, 93–94

 cholecystolithiasis, 91

 choledocholithiasis, 91–92

 cysts, 105–110

 future directions in, 94–95

 pancreas divisum, 91, 101

 pancreatitis, 93, 101–104

versus pancreatic cancer, 104–105

 postoperative biliary complications, 92–93

 primary sclerosing cholangitis, 92

 santoriniceles, 101

 technique for, 89–90, 97–99

versus endoscopic retrograde cholangiopancreatography, 89, 99–100

Pancreatitis, MR cholangiopancreatography of, 93, 101–104

- versus pancreatic cancer, MR cholangiopancreatography of, 104–105
- Paramagnetic contrast agents, in MR angiography, of chest, 30–31
- Pelvic floor relaxation, MR imaging of, 188–189
- Pelvis, female. *See* Female pelvis.
- Perfusional contrast agents, in MR imaging, 55–56
- Pericardial disease, MR imaging of, 23–24
- Peripheral arterial occlusive disease, MR angiography of, 133–136, 138
- Phase-contrast MR angiography, technique for, 115–116
- Phase ordering with automatic window selection, in MR imaging, 5
- Pheochromocytomas, adrenal, MR imaging of, 155–156
bladder, MR imaging of, 170
- Polycystic ovarian disease, MR imaging of, 184–185
- Portal hypertension, in cirrhosis, MR imaging of, 74
- Portal vein thrombosis, MR imaging of, 81, 84
- Pregnancy, MR imaging in, 189–190
- Primary sclerosing cholangitis, MR cholangiopancreatography of, 92
MR imaging of, 74
- Pseudocysts, adrenal, MR imaging of, 156–157
pancreatic, MR cholangiopancreatography of, 105–106
- Pseudosarcomas, bladder, MR imaging of, 171
- Pseudotumors, bladder, MR imaging of, 171
- Pulmonary arteries, MR angiography of, 37–39
- Pulse sequences, in MR angiography, 32–33, 121–123
in MR imaging. *See* Magnetic resonance imaging.

R

- Renal artery stenosis, MR angiography of, 130
- Renal cell carcinoma, MR imaging of, 146–148
- Renal hamartomas, MR imaging of, 148–150
- Renal transplant, postoperative evaluation of, MR angiography in, 130–131, 133
- Respiratory ordered phase encoding, in MR imaging, 4–5
- Rest imaging, of cardiovascular disease, 17

- Restrictive cardiomyopathy, MR imaging of, 23
- Rhabdomyosarcomas, bladder, MR imaging of, 171
- Right ventricular dysplasia, arrhythmogenic, MR imaging of, 21–22

S

- Santoriniceles, MR cholangiopancreatography of, 101
- Secretin-enhanced dynamic MR cholangiopancreatography, technique for, 99
- Segmented volume acquisition, in MR angiography, 139
- Serous microcystic adenomas, MR cholangiopancreatography of, 107
- Spiral MR imaging, physics of, 9–12
- Steady-state free precession, in MR angiography, 33
- Steatosis, MR imaging of, 77–79
- Stein-Leventhal syndrome, MR imaging of, 184–185
- Stress imaging, of cardiovascular disease, 17–18

T

- Teratomas, MR imaging of, 185
- Teslascan, in MR imaging, 54–55
- Thoracic aorta, MR angiography of, 34
- Thoracic veins, central, MR angiography of, 37
- Time-of-flight MR angiography, technique for, 115–116
- Time-resolved two- and three-dimensional digital subtraction angiography, technique for, 139
- Tubo-ovarian complex, MR imaging of, 185–186
- Tumors, bladder, MR imaging of. *See* Bladder.

U

- Unicornuate uterus, MR imaging of, 181
- Urography, MR, technique for, 146
- Uterus didelphys, MR imaging of, 181

V

- Valvular heart disease, MR imaging of, 21
- Ventricular function, MR imaging of, 25
- Vesical congestion, of bladder, MR imaging of, 172